[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509672":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":38,"centralContacts":45,"locations":54,"responsibleParty":154,"collaborators":157,"id":162,"slug":163,"hasResults":164,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":164,"sex":169,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":175,"studyType":176,"phases":10,"briefSummary":177,"conditions":178,"keywords":10,"overallStatus":111,"whyStopped":10,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Bleeding disorder using LNG-IUD",null,"Adolescents and young adults ages 10-24 with diagnosed bleeding disorder planning use of LNG-IUD.",[13],"Drug: Levonorgestrel Intrauterine System",{"label":15,"type":10,"description":16,"interventionNames":17},"Non-bleeding disorder using LNG-IUD","Adolescents and young adults ages 10-24 without diagnosed bleeding disorder planning use of LNG-IUD.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Bleeding disorder using NETA","Adolescents and young adults ages 10-24 with diagnosed bleeding disorder planning use of NETA.",[22],"Drug: Norethindrone Acetate",[24,32],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Levonorgestrel Intrauterine System","52 mg levonorgestrel intrauterine system",[9,15],[30,31],"Mirena","Liletta",{"type":25,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Norethindrone Acetate","norethindrone acetate 5 mg daily",[19],[37],"Aygestin",[39,42],{"name":40,"affiliation":5,"role":41},"Maureen Baldwin, MD MPH","PRINCIPAL_INVESTIGATOR",{"name":43,"affiliation":44,"role":41},"Allison Wheeler","University of Washington",[46,51],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":50},"OHSU Women's Health Research Unit","CONTACT","5034943666","whru@ohsu.edu",{"name":40,"role":48,"phone":52,"phoneExt":10,"email":53},"5034949762","schaum@ohsu.edu",[55,69,79,89,99,109,124,134,148],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":10},"Stanford","NOT_YET_RECRUITING","Palo Alto","California","94304","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-122.14302,37.44188,{"lat":67,"lon":66},{"facility":70,"status":57,"city":71,"state":72,"zip":73,"country":61,"countryCode":62,"cosmosGeoPoint":74,"geoPoint":78,"contacts":10},"Colorado Anschutz Medical Campus","Aurora","Colorado","80045",{"type":64,"coordinates":75},[76,77],-104.83192,39.72943,{"lat":77,"lon":76},{"facility":80,"status":57,"city":81,"state":82,"zip":83,"country":61,"countryCode":62,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Emory","Atlanta","Georgia","30322",{"type":64,"coordinates":85},[86,87],-84.38798,33.749,{"lat":87,"lon":86},{"facility":90,"status":57,"city":91,"state":92,"zip":93,"country":61,"countryCode":62,"cosmosGeoPoint":94,"geoPoint":98,"contacts":10},"University of Michigan Medicine","Ann Arbor","Michigan","48109",{"type":64,"coordinates":95},[96,97],-83.74088,42.27756,{"lat":97,"lon":96},{"facility":100,"status":57,"city":101,"state":102,"zip":103,"country":61,"countryCode":62,"cosmosGeoPoint":104,"geoPoint":108,"contacts":10},"Children's Mercy","Kansas City","Missouri","64108",{"type":64,"coordinates":105},[106,107],-94.57857,39.09973,{"lat":107,"lon":106},{"facility":110,"status":111,"city":112,"state":113,"zip":114,"country":61,"countryCode":62,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Oregon Health & Science University","RECRUITING","Portland","Oregon","97239",{"type":64,"coordinates":116},[117,118],-122.67621,45.52345,{"lat":118,"lon":117},[121],{"name":122,"role":48,"phone":123,"phoneExt":10,"email":50},"Women's Health Research Unit","503-494-3666",{"facility":125,"status":57,"city":126,"state":127,"zip":128,"country":61,"countryCode":62,"cosmosGeoPoint":129,"geoPoint":133,"contacts":10},"Penn State Health","Hershey","Pennsylvania","17003",{"type":64,"coordinates":130},[131,132],-76.65025,40.28592,{"lat":132,"lon":131},{"facility":44,"status":57,"city":135,"state":136,"zip":137,"country":61,"countryCode":62,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Seattle","Washington","98101",{"type":64,"coordinates":139},[140,141],-122.33207,47.60621,{"lat":141,"lon":140},[144],{"name":145,"role":48,"phone":146,"phoneExt":10,"email":147},"Washington Center for Bleeding Disorders","206-614-1200","WICResearch@WACBD.org",{"facility":149,"status":57,"city":135,"state":136,"zip":150,"country":61,"countryCode":62,"cosmosGeoPoint":151,"geoPoint":153,"contacts":10},"Seattle Children's Hospital","98105",{"type":64,"coordinates":152},[140,141],{"lat":141,"lon":140},{"type":41,"investigatorFullName":155,"investigatorTitle":156,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Maureen Baldwin","Associate Professor of Ob\u002FGyn",[158,159],{"name":44,"class":6},{"name":160,"class":161},"NIH National Heart, Lung, and Blood Institute","UNKNOWN","100509672","heavy-menstrual-bleeding-progestin-treatment-in-bleeding-disorders-study-100509672",false,"NCT05916469","Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study","HMB-BD","Inclusion Criteria:\n\n* Post-menarcheal\n* Ages 10-24\n* Decision to initiate a trial of progestin therapy with either LNG-IUD or NETA\n* Able to provide assent and written informed consent by one parent (ages \\\u003C18) or written informed consent (age 18+)\n* Must meet trial criteria for heavy menstrual bleeding\n* Must meet trial criteria for a bleeding disorder or have minimum workup to rule out bleeding disorder\n\nExclusion Criteria:\n\n* Pregnant or seeking pregnancy","FEMALE","10 Years","24 Years",{"count":173,"type":174},300,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months of use of either of two commonly used hormonal treatments for menstrual suppression - levonorgestrel intrauterine device (LNG-IUD) and norethindrone acetate (NETA). Under this application the study will compare the two treatments and compare outcomes after LNG-IUD treatment results to a control group without a bleeding disorder, with the goal of determining the benefits and expected outcomes of these treatment options for this population.",[179,180,181],"Heavy Menstrual Bleeding","Bleeding Disorder","Von Willebrand Diseases","2025-12-09",{"date":184,"type":185},"2025-12-17","ACTUAL",{"date":187,"type":185},"2025-09-24",{"date":189,"type":174},"2029-06",{"name":5,"class":6},9]